MCC
TCRT icon

Money Concepts Capital’s Alaunos Therapeutics TCRT Stock Holding History

Money Concepts Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed -$325 – 2627
2022
Q4 		$325 Buy
+3
New +$435 ﹤0.01% 3059

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Money Concepts Capital's TCRT Position: Q1 2023 in Review

Money Concepts Capital sold out of Alaunos Therapeutics (TCRT) in Q1 2023, closing a stake of 3 shares — an estimated $325 sold.

Money Concepts Capital first reported a position in TCRT in Q4 2022 and held it in 1 quarter. The position peaked at $325 in Q4 2022. 108 funds tracked by Wall St. Rank hold TCRT as of Q1 2023.

  • Money Concepts Capital reported no remaining Alaunos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 3 Alaunos Therapeutics shares in Q1 2023, an estimated $325.
  • Money Concepts Capital first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's Alaunos Therapeutics position peaked at $325 in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.